What does CUSIP 68232V884 represent in this 13F holders report?

CUSIP 68232V884 is the security identifier for TRAW - Traws Pharma, Inc. - Common stock, par value $.01 per share used to aggregate holder disclosures.

How many institutions held TRAW - Traws Pharma, Inc. - Common stock, par value $.01 per share in Q1 2025?

18 institutional investors reported TRAW - Traws Pharma, Inc. - Common stock, par value $.01 per share for Q1 2025. Use the holders table for investor-level position and value details.

Traws Pharma, Inc. - Common stock, par value $.01 per share (TRAW)

CUSIP: 68232V884

Q1 2025 13F Holders as of 31 Mar 2025

Type / Class: Equity / Common stock, par value $.01 per share
Shares outstanding: 8,133,373
Total 13F shares: 1,732,309
Share change: +557,029
Total reported value: $3,984,315
Price per share: $2.30
Number of holders: 18
Value change: +$1,207,345
Number of buys: 10
Number of sells: 7

Quarterly Holders Quick Answers

What is CUSIP 68232V884?
CUSIP 68232V884 identifies TRAW - Traws Pharma, Inc. - Common stock, par value $.01 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q2 2025
Previous quarter: Q4 2024

Recent filing periods for CUSIP 68232V884:

Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024

Top shareholders of TRAW - Traws Pharma, Inc. - Common stock, par value $.01 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
ORBIMED ADVISORS LLC	13F 13D/G 3/4/5	Company · 10%+ Owner	20% from 13D/G	605,531	$5,377,115	—	31 Dec 2024	13F 13D/G 3/4/5
Viriom, Inc.	3/4/5	10%+ Owner	— class O/S missing	1,645,100	$1,480,590	—	03 Apr 2024	3/4/5
PERCEPTIVE ADVISORS LLC	13F	Company	2%	164,157	$1,457,714	—	31 Dec 2024	13F
Alyeska Investment Group, L.P.	13F 13D/G	Company	9.9% from 13D/G	116,714	$1,036,420	—	31 Dec 2024	13F 13D/G
Ikarian Capital, LLC	13F	Company	1.2%	98,493	$874,618	—	31 Dec 2024	13F
Vestal Point Capital, LP	13F	Company	0.92%	75,000	$666,000	—	31 Dec 2024	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.26%	20,801	$184,727	—	31 Dec 2024	13F
MORGAN STANLEY	13F	Company	0.19%	15,725	$139,638	—	31 Dec 2024	13F
VANGUARD GROUP INC	13F	Company	0.16%	13,141	$116,693	—	31 Dec 2024	13F
BOOTHBAY FUND MANAGEMENT, LLC	13F	Company	0.35%	28,431	$108,177	—	31 Dec 2024	13F
Steven M. Fruchtman	3/4/5	PRESIDENT, CHIEF EXECUTIVE OFF, Director	— mixed-class rows	121,014 mixed-class rows	$98,282	—	13 Mar 2024	3/4/5
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.12%	10,052	$89,262	—	31 Dec 2024	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.12%	10,012	$88,907	—	31 Dec 2024	13F
BlackRock, Inc.	13F	Company	0.12%	9,956	$88,409	—	31 Dec 2024	13F
Abraham N. Oler	3/4/5	SVP Corp Dev & Gen Counsel	— mixed-class rows	96,197 mixed-class rows	$36,818	—	07 Feb 2022	3/4/5
Mark Patrick Guerin	3/4/5	Chief Financial Officer	— mixed-class rows	44,755 mixed-class rows	$23,400	—	05 Feb 2025	3/4/5
Mark S. Gelder MD	3/4/5	CHIEF MEDICAL OFFICER	— mixed-class rows	82,667 mixed-class rows	$13,847	—	13 Mar 2023	3/4/5
GROUP ONE TRADING LLC	13F	Company	0.01%	1,164	$10,336	—	31 Dec 2024	13F
UBS Group AG	13F	Company	0.01%	791	$7,024	—	31 Dec 2024	13F
Vermillion & White Wealth Management Group, LLC	13F	Company	0%	205	$1,820	—	31 Dec 2024	13F
SBI Securities Co., Ltd.	13F	Company	0%	155	$1,376	—	31 Dec 2024	13F
BANK OF AMERICA CORP /DE/	13F	Company	0%	76	$675	—	31 Dec 2024	13F
Pacific Capital Wealth Advisors, Inc.	13F	Company	0%	2	$18	—	31 Dec 2024	13F
Cornerstone Planning Group LLC	13F	Company	— class O/S missing	1	$7	—	31 Dec 2024	13F
Luba Greenwood	3/4/5	Director	— class O/S missing	164,000	—	—	16 Sep 2024	3/4/5
Victor M. Moyo	3/4/5	CHIEF MEDICAL OFFICER	— class O/S missing	125,000	—	—	02 Oct 2023	3/4/5
James J. Marino	3/4/5	Director	— class O/S missing	66,468	—	—	10 Aug 2023	3/4/5
Jerome Groopman	3/4/5	Director	— class O/S missing	66,468	—	—	10 Aug 2023	3/4/5
Peter Atadja	3/4/5	Director	— class O/S missing	66,468	—	—	10 Aug 2023	3/4/5
Viren Mehta	3/4/5	Director	— class O/S missing	66,468	—	—	10 Aug 2023	3/4/5

Institutional Holders of Traws Pharma, Inc. - Common stock, par value $.01 per share (TRAW) as of Q1 2025

As of 31 Mar 2025, Traws Pharma, Inc. - Common stock, par value $.01 per share (TRAW) was held by 18 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 1,732,309 shares. The largest 10 holders included ORBIMED ADVISORS LLC, PERCEPTIVE ADVISORS LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., Vestal Point Capital, LP, Alyeska Investment Group, L.P., GEODE CAPITAL MANAGEMENT, LLC, BOOTHBAY FUND MANAGEMENT, LLC, Ikarian Capital, LLC, UBS Group AG, and VANGUARD GROUP INC. This page lists 18 institutional shareholders reporting positions in this security for the Q1 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q1 2025 vs Q4 2024 Across Filers

Q4 2024 holders

Q1 2025 holders

Holder diff

Investor	Q4 2024 Shares	Q1 2025 Shares	Share Diff	Share Chg %	Q4 2024 Value $	Q1 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.